Analystreport

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) had its "buy" rating re-affirmed by analysts at Brookline Capital Management.

Cyclacel Pharmaceuticals, Inc.  (CYCC) 
Last cyclacel pharmaceuticals, inc. earnings: 2/26 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.cyclacel.com/investor-relations